Jury Still Out On Success Of FDA's Warning Letter Close-Out Program
This article was originally published in The Gray Sheet
Executive Summary
FDA is extending its warning letter "close-out" pilot program to learn more about its value, even as grumblings begin that the program may not be all it was cracked up to be.
You may also be interested in...
FDA's New Enforcement Approach Will Put More Warning Letters In The Mail
FDA Commissioner Margaret Hamburg is honing the agency's enforcement system to get warning letters out faster and create a formal "close-out" process that publicly indicates when a firm has addressed FDA's concerns
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.